Rite Aid Corporation (RAD) is scheduled to report second quarter 2019 earnings on Thursday. Analysts expect the company to report revenues of $5.37 billion, down 30% year-over-year, along with a loss of $0.01 per share.
Weakness in the generic drug market has been negatively impacting the stock, which does not present a positive picture to investors. Generic drug purchasing efficiencies are expected to be lower by around $80 million than when Rite Aid first charted its fiscal year 2019 guidance.
Last month, Rite Aid also terminated its merger agreement with Albertsons Companies Inc. and committed itself to executing its strategic plan as a standalone company. The company’s plan to leverage its retail pharmacies, health and wellness offerings along with its EnvisionRxOptions PBM provides some optimism though.
The company has missed estimates twice in the recent past and despite optimism on its strategic plan, the generic drug market conditions have dampened the sentiment surrounding the stock and there is a chance that Rite Aid might not bring a positive surprise this quarter. The stock has dropped 15% over the past one month.
During the first quarter, the company had posted a profit of $214.4 million or $0.20 per share, driven by one-time gains from the sale of its stores to Walgreens Boots Alliance (WBA). Net loss from continuing operations came in at $0.04 per share as a result of higher lease termination and impairment charges.
Total revenues in the first quarter fell 2% to $3.9 billion primarily due to store closures while revenues from continuing operations dropped 1% due to weaknesses in the Retail Pharmacy and Pharmacy Services segments.
For the full year of 2019, the retailer has guided for revenues of $21.7 billion to $22.1 billion with same-store sales expected to be flat to up 1%. In August, Rite Aid updated its outlook for net loss based on negative trends in the generic drug marketplace. Adjusted net loss is expected to range from $0.04 to breakeven per share versus the previous earnings range of $0.02 to $0.06 per share.
Most Popular
CL Earnings: Key quarterly highlights from Colgate-Palmolive’s Q2 2024 financial results
Colgate-Palmolive Company (NYSE: CL) reported its second quarter 2024 earnings results today. Net sales increased 4.9% year-over-year to $5 billion. Organic sales increased 9%. Net income attributable to Colgate-Palmolive Company was $731
Key takeaways from Visa’s Q3 2024 earnings report
Credit card behemoth Visa, Inc. (NYSE: V) this week reported mixed results for the June quarter, with earnings matching expectations and sales slightly missing the view. Both numbers grew in
Southwest Airlines (LUV): A look at the airline’s performance in Q2 2024
Shares of Southwest Airlines Co. (NYSE: LUV) were up over 6% on Thursday after the company beat earnings estimates for the second quarter of 2024. The stock has gained 4%
